Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
J Exp Clin Cancer Res. 2021 Dec 2;40(1):382. doi: 10.1186/s13046-021-02153-9.
J Exp Clin Cancer Res. 2021.
PMID: 34857016
Free PMC article.